- For use in acute respiratory infections in combination with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhea in combination with oral rehydration therapy, to reduce clinical signs in calves over one week of age and non-lactating young cattle. For the relief of post-operative pain in calves after dehorning.
- For use in non-infectious musculoskeletal disorders to reduce the symptoms of lameness and inflammation. For relief of post-operative pain associated with minor soft tissue surgery such as castration.
- Relief of inflammation and pain in both acute and chronic musculoskeletal disorders. Reduction of post-operative pain and inflammation after orthopedic and soft tissue surgery.
- Reduction of post-operative pain after ovariohysterectomy and after minor soft tissue surgery.
Cattle and pigs:
- Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disease, or if there is evidence of ulcerogenic gastrointestinal lesions. Do not use in case of hypersensitivity to the active substance or to any of the excipients. For the treatment of diarrhea in cattle, do not use in animals less than one week old. Do not use in pigs less than 2 days old.
Dogs and cats:
- Do not use in pregnant or lactating animals. Not for use in animals suffering from gastrointestinal disorders such as irritation and bleeding, impaired liver, heart or kidney function and coagulation disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in animals under 6 weeks of age and in cats weighing less than 2 kg.
Melosolute 5 mg/ml is a solution for injection.
- A single subcutaneous or intravenous injection of 0.5 mg meloxicam/kg body weight (i.e. 10.0 ml/100 kg body weight), in combination with antibiotic therapy or oral rehydration therapy.
- Musculoskeletal disorders: A single intramuscular injection of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/25 kg body weight). If necessary, a second dose of meloxicam can be given after 24 hours. Reduction of post-operative pain: A single intramuscular injection at a dose of 0.4 mg meloxicam/kg body weight (i.e. 0.4 ml/5 kg body weight) before surgery. Care should be taken regarding accurate dosing, including the use of an appropriate dosing device and careful estimation of body weight.
- Single administration of 0.2 mg meloxicam per kg body weight (i.e. 0.4 ml/10 kg body weight). Musculoskeletal disorders: single subcutaneous injection. For continued treatment, meloxicam 1.5 mg/ml oral suspension for dogs can be used at a dose of 0.1 mg meloxicam per kg body weight, 24 hours after administration of the injection. Reduction of post-operative pain (over a 24-hour period): single intravenous or subcutaneous injection before surgery, e.g. in the induction phase of anaesthesia.
- Single administration of 0.3 mg meloxicam per kg body weight (i.e. 0.06 ml/kg body weight). Reduction of post-operative pain after ovariohysterectomy and after minor soft tissue surgery: single subcutaneous injection before surgery, eg during the induction phase of anaesthesia. The stopper should not be pierced more than 20 times.
One ml contains:
Meloxicam 5 mg
Ethanol (E1510) 150 mg
Melosolute 5 mg/ml is available in a 20 ml vial.
Cattle and pigs:
Subcutaneous and intramuscular administration (in cattle) and intramuscular administration (in pigs) is well tolerated; only minor transient swelling at the injection site following subcutaneous administration was seen in less than 10% of cattle treated in the clinical trial. In very rare cases anaphylactic reactions can occur which can be serious (including fatal). These should be treated symptomatically.
Dogs and cats:
Typical side effects of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have been reported occasionally. Elevated liver enzymes have been reported in very rare cases. Very rare cases of bloody diarrhoea, hemorrhage and gastrointestinal ulceration have been reported in dogs. In dogs, these side effects usually occur within the first week of treatment and in most cases are transient and resolve on discontinuation, but in very rare cases can be serious or fatal. In very rare cases, anaphylactic reactions may occur. These should be treated symptomatically.
The frequency of side effects is defined as follows:
- Very common (more than 1 in 10 animals treated show side effect(s))
- Common (more than 1 but less than 10 out of 100 animals treated)
- Uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- Rare (more than 1 but less than 10 animals in 10,000 animals treated)
- Very rare (less than 1 in 10,000 animals treated, including isolated reports)
If side effects occur, treatment should be discontinued.